Highlights
- Market Cap
- $241.64M
- Enterprise Value
- $136.07M
- EPS (TTM)
- -$0.68
- Total Revenue (TTM)
- $663.00K
- Gross Profit (TTM)
- -$730.00K
- EBITDA (TTM)
- -$61.04M
- Year Range
- $0.46 - $7.13
- Target Price
- $4.67
- ROA (TTM)
- -27.00%
- ROE (TTM)
- -30.12%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ProKidney Corp., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
ProKidney Corp. (PROK) has returned -20.09% so far this year and 104.29% over the past 12 months.
ProKidney Corp.
- 1D
- 10.49%
- 1M
- -20.09%
- YTD
- -20.09%
- 6M
- -26.03%
- 1Y
- 104.29%
- 3Y*
- -45.92%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jul 12, 2022, PROK's average daily return is +0.45%, while the average monthly return is +4.60%. At this rate, your investment would double in approximately 1.3 years.
Historically, 44% of months were positive and 56% were negative. The best month was Jul 2025 with a return of +367.8%, while the worst month was Oct 2023 at -64.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, PROK closed higher 48% of trading days. The best single day was Jul 8, 2025 with a return of +515.0%, while the worst single day was Oct 12, 2023 at -31.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.61% | 13.13% | -20.09% | -20.09% | |||||||||
| 2025 | -2.37% | -25.45% | -28.76% | 1.07% | -18.38% | -18.08% | 367.83% | -14.80% | 2.54% | 26.45% | -27.45% | 0.90% | 32.54% |
| 2024 | -26.40% | 24.43% | 0.61% | 25.91% | 68.52% | -29.31% | -4.88% | 2.56% | -20.00% | -16.67% | 25.00% | -15.50% | -5.06% |
| 2023 | 52.04% | 12.08% | -3.17% | -16.61% | 28.60% | -7.83% | 14.57% | -33.07% | -46.62% | -64.41% | 3.07% | 5.95% | -74.05% |
| 2022 | 14.02% | -2.44% | -6.15% | 12.32% | -9.98% | -24.70% | -20.51% |
Benchmark Metrics
ProKidney Corp. has an annualized alpha of 130.23%, beta of 1.83, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 13, 2022.
- This stock participated in 272.41% of S&P 500 Index downside but only 164.86% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 130.23%
- Beta
- 1.83
- R²
- 0.01
- Upside Capture
- 164.86%
- Downside Capture
- 272.41%
Return for Risk
Risk / Return Rank
PROK ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ProKidney Corp. (PROK) and compare them to a chosen benchmark (S&P 500 Index).
| PROK | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.20 | 0.90 | -0.70 |
Sortino ratioReturn per unit of downside risk | 6.11 | 1.39 | +4.73 |
Omega ratioGain probability vs. loss probability | 1.70 | 1.21 | +0.49 |
Calmar ratioReturn relative to maximum drawdown | 1.40 | 1.40 | 0.00 |
Martin ratioReturn relative to average drawdown | 2.05 | 6.61 | -4.55 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore PROK risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the ProKidney Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ProKidney Corp. was 96.29%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current ProKidney Corp. drawdown is 87.01%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.29% | Mar 14, 2023 | 520 | Apr 8, 2025 | — | — | — |
| -51.93% | Nov 14, 2022 | 31 | Dec 28, 2022 | 27 | Feb 7, 2023 | 58 |
| -41.33% | Jul 27, 2022 | 18 | Aug 19, 2022 | 59 | Nov 11, 2022 | 77 |
| -19.95% | Jul 15, 2022 | 1 | Jul 15, 2022 | 4 | Jul 21, 2022 | 5 |
| -9.24% | Feb 14, 2023 | 5 | Feb 21, 2023 | 14 | Mar 13, 2023 | 19 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ProKidney Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ProKidney Corp. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PROK relative to other companies in the Biotechnology industry. Currently, PROK has a P/S ratio of 360.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PROK in comparison with other companies in the Biotechnology industry. Currently, PROK has a P/B value of 0.8. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |